These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26820829)

  • 41. Usefulness of platelet function tests to predict bleeding with antithrombotic medications.
    Gorog DA; Otsui K; Inoue N
    Cardiol Rev; 2015; 23(6):323-7. PubMed ID: 25839991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of antibodies that interfere with the collagen-VWF-GPIb axis as new antithrombotics.
    Deckmyn H; Cauwenberghs N; Wu D; Depraetere H; Vanhoorelbeke K
    Verh K Acad Geneeskd Belg; 2005; 67(1):55-65. PubMed ID: 15828307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
    Hennan JK; Swillo RE; Morgan GA; Leik CE; Brooks JM; Shaw GD; Schaub RG; Crandall DL; Vlasuk GP
    Thromb Haemost; 2006 Mar; 95(3):469-75. PubMed ID: 16525575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period.
    Hall R; Mazer CD
    Anesth Analg; 2011 Feb; 112(2):292-318. PubMed ID: 21212258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Konstantopoulos K; Mousa SA
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
    Bird JE; Giancarli MR; Allegretto N; Barbera F; Wong P; Schumacher WA; Ogletree ML; Seiffert D
    Thromb Res; 2008; 123(1):146-58. PubMed ID: 18479740
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting platelet GPIbβ reduces platelet adhesion, GPIb signaling and thrombin generation and prevents arterial thrombosis.
    Maurer E; Tang C; Schaff M; Bourdon C; Receveur N; Ravanat C; Eckly A; Hechler B; Gachet C; Lanza F; Mangin PH
    Arterioscler Thromb Vasc Biol; 2013 Jun; 33(6):1221-9. PubMed ID: 23559635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR
    Catheter Cardiovasc Interv; 2008 May; 71(6):816-21. PubMed ID: 18412079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The platelet P2 receptors in arterial thrombosis.
    Gachet C; Léon C; Hechler B
    Blood Cells Mol Dis; 2006; 36(2):223-7. PubMed ID: 16466948
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiplatelet agents in acute coronary syndromes.
    Sakhuja R; Yeh RW; Bhatt DL
    Curr Probl Cardiol; 2010 Mar; 35(3):123-70. PubMed ID: 20152547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
    Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
    Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International Society of Thrombosis and Hemostasis--XIXth Congress 12-18 July 2003, Birmingham, UK.
    Shah S
    IDrugs; 2003 Sep; 6(9):858-61. PubMed ID: 14565174
    [No Abstract]   [Full Text] [Related]  

  • 54. [Antithrombotic treatments and inherited bleeding disorders].
    Casini A; Fontana P; Lecompte T
    Rev Med Suisse; 2018 Dec; 14(630):2207-2210. PubMed ID: 30516888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of the post-aspirin bleeding time.
    Hindman BJ; Koka BV
    Anesthesiology; 1986 Mar; 64(3):368-70. PubMed ID: 3456732
    [No Abstract]   [Full Text] [Related]  

  • 56. Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH.
    Khorsand N; Majeed A; Sarode R; Beyer-Westendorf J; Schulman S; Meijer K;
    J Thromb Haemost; 2016 Jan; 14(1):211-4. PubMed ID: 26391431
    [No Abstract]   [Full Text] [Related]  

  • 57. Attacking the system: Next-generation auto-immune therapies target pathways rather than symptoms.
    Hunter P
    EMBO Rep; 2015 Apr; 16(4):411-5. PubMed ID: 25744524
    [No Abstract]   [Full Text] [Related]  

  • 58. Dental treatment in the era of new anti-thrombotic agents.
    Sahar-Helft S; Chackartchi T; Polak D; Findler M
    Int Dent J; 2018 Jun; 68(3):131-137. PubMed ID: 28921533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons.
    Huang HP; Lin WH; Chen SG; Chen LZ; Chen MY; Che CH
    Mol Neurobiol; 2017 Mar; 54(2):1456-1466. PubMed ID: 26846361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Very late ischemic complications in flow-diverter stents: a retrospective analysis of a single-center series.
    Guédon A; Clarençon F; Di Maria F; Rosso C; Biondi A; Gabrieli J; Rojas P; Chiras J; Sourour N
    J Neurosurg; 2016 Oct; 125(4):929-935. PubMed ID: 26824382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.